Search Trials
For best results, use specific search terms. For example, instead of "brain tumor," try "glioblastoma." You can also contact the Clinical Trials Office at 312-695-1102 for assistance.
Phase 2 study of XL092 as first line therapy in radioiodine refractory differentiated thyroid cancerThis study assesses efficacy of treatment with XL092 (Zanzalintinib) in radioactive iodine refractory Differentiated Thyroid Cancer patients by evaluating the proportion of patients alive and without progression at 12 months, by evaluating Progression Free Survival, evaluating the overall survival time, safety and tolerability of the study drug and characterize the quality of life. Along with that the study would assess immune cell landscape before and after the treatment, and study genomic changes before and after treatment. The duration for this study will last for approximately 26 months or until the time of progression of cancer. The participant will be asked to start the treatment within 14 days of screening. XL092 (study drug) is an oral agent and will be provided as tablets at 100mg dose to be taken by mouth once a day. Each treatment cycle is 21 days (every three weeks). Participants will be followed from the end of study treatment either at a routine clinic visit or by phone call every 3 months for 12 months to document survival, patient health status and disease progression. Eligibility Criteria
Location(s) |